Inventor · disambiguated record
Esther Maria Furrer
Also filed as: FURRER ESTHER · FURRER ESTHER MARIA
9 granted patents·6 pending applications·31 citations·filing 2009–2024
82Inventor score
Top patents by PatentIndex Score
15 records- 0188US8697074B2Methods and compositions for enhanced delivery of macromoleculesHULMANN-COTTIER VALERIE·Filed 2009·Granted Apr 15, 2014·24 cites·15 claims
- 0286US11459383B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2017·Granted Oct 4, 2022·5 cites·20 claims
- 0381US11472872B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Oct 18, 2022·2 cites·13 claims
- 0479US12209122B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2022·Granted Jan 28, 2025·0 cites·26 claims
- 0575US2025122275A1Antibody variantsTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 0674US12043663B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2022·Granted Jul 23, 2024·0 cites·16 claims
- 0772US2024343793A1Antibody variantsTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 0868US2024000714A1Topical treatment of inflammatory bowel disease using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2023·Application pending·0 cites
- 0967US2025051431A2Antibody VariantsTILLOTTS PHARMA AG·Filed 2022·Application pending·0 cites
- 1061US11717484B2Topical treatment of inflammatory bowel disease using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2018·Granted Aug 8, 2023·0 cites·13 claims
- 1160US11999781B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Jun 4, 2024·0 cites·5 claims
- 1257US12215146B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Feb 4, 2025·0 cites·5 claims
- 1350US2014212421A1Methods and compositions for enhanced delivery of macromoleculesESBATECH ALCON BIOMED RES UNIT·Filed 2014·Application pending·0 cites
- 1445US10975143B2Anti-TNF-α-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2017·Granted Apr 13, 2021·0 cites·20 claims
- 1537US2022119515A1Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →